Recent Investment Analysts’ Ratings Updates for Immunome (IMNM)

Immunome (NASDAQ: IMNM) recently received a number of ratings updates from brokerages and research firms:

• 10/16/2026 – Immunome is now covered by William Blair. They set an “outperform” rating on the stock.
• 10/15/2026 – Immunome had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 10/4/2026 – Immunome was downgraded by Wall Street Zen from “sell” to “strong sell”.
• 9/30/2026 – Immunome is now covered by Stifel Nicolaus. They set a “hold” rating and a $24.00 price target on the stock.
• 9/26/2026 – Immunome was upgraded by Wall Street Zen from “strong sell” to “sell”.
• 9/21/2026 – Immunome is now covered by Alliance Global Partners. They set a “buy” rating and a $32.00 price target on the stock.
• 9/10/2026 – Immunome had its “buy” rating reaffirmed by HC Wainwright. They now have a $40.00 price target on the stock.

Insiders Place Their Bets

In other Immunome news, Director Isaac Barchas sold 11,048 shares of the stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $27.25, for a total transaction of $301,058.00. Following the completion of the transaction, the director directly owned 92,211 shares of the company’s stock, valued at approximately $2,512,749.75. This trade represents a 10.70% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Jack Higgins sold 13,200 shares of Immunome stock in a transaction on Friday, September 11th. The shares were sold at an average price of $25.32, for a total value of $334,224.00. Following the transaction, the insider owned 65,050 shares in the company, valued at approximately $1,647,066. This trade represents a 16.87% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 223,368 shares of company stock worth $5,747,142 over the last ninety days. Company insiders own 7.21% of the company’s stock.

Immunome, Inc (NASDAQ: IMNM) is a clinical-stage biopharmaceutical company focused on discovering and developing antibody-based medicines. Its technology platform analyzes human immune responses to identify antibodies that may be developed into therapies for serious diseases.

The company’s research activities have included therapeutic programs in oncology and immunology, with an emphasis on antibodies designed to affect disease-driving biological pathways. Immunome has also conducted antibody discovery work related to infectious diseases, including SARS-CoV-2, as it has expanded its focus toward broader therapeutic applications.

Immunome is headquartered in Exton, Pennsylvania, and serves the global biopharmaceutical market through internal research and development activities and potential collaborations.